DÄ internationalArchive10/2020Amyloidosis—the diagnosis and treatment of an underdiagnosed disease

Review article

Amyloidosis—the diagnosis and treatment of an underdiagnosed disease

Dtsch Arztebl Int 2020; 117: 159-66. DOI: 10.3238/arztebl.2020.0159

Ihne, S; Morbach, C; Sommer, C; Geier, A; Knop, S; Störk, S

For technical reasons, the English full text will be published approximately two weeks after the German print edition has been published.

Interdisziplinäres Amyloidosezentrum Nordbayern, Universitätsklinikum Würzburg:
Dr. med. Sandra Ihne, Dr. med. Caroline Morbach, Prof. Dr. med. Claudia Sommer,
Prof. Dr. med. Andreas Geier, Prof. Dr. med. Stefan Knop, Prof. Dr. med. Stefan Störk, PhD
Medizinische Klinik und Poliklinik II, Hämatologie, Universitätsklinikum Würzburg:
Dr. med. Sandra Ihne, Prof. Dr. med. Stefan Knop
Deutsches Zentrum für Herzinsuffizienz (DZHI), Universität und Universitätsklinikum Würzburg:
Dr. med. Sandra Ihne, Dr. med. Caroline Morbach, Prof. Dr. med. Stefan Störk, PhD
Medizinische Klinik und Poliklinik I, Kardiologie, Universitätsklinikum Würzburg:
Dr. med. Caroline Morbach, Prof. Dr. med. Stefan Störk, PhD
Neurologische Klinik, Universitätsklinikum Würzburg: Prof. Dr. med. Claudia Sommer
Medizinische Klinik und Poliklinik II, Hepatologie, Universitätsklinikum Würzburg:
Prof. Dr. med. Andreas Geier
1.Palladini G, Merlini G: What is new in diagnosis and management of light chain amyloidosis? Blood 2016; 128: 159–68 CrossRef MEDLINE
2.Gillmore JD, Damy T, Fontana M, et al.: A new staging system for cardiac transthyretin amyloidosis. Eur Heart J 2018; 39: 2799–806 CrossRef MEDLINE
3.Gertz MA: Immunoglobulin light chain amyloidosis diagnosis and treatment algorithm 2018. Blood Cancer J 2018; 8: 44 CrossRef MEDLINE PubMed Central
4.Merlini G, Dispenzieri A, Sanchorawala V, et al.: Systemic immunoglobulin light chain amyloidosis. Nat Rev Dis Primers 2018; 4: 38 CrossRef MEDLINE
5.Schmidt HH, Waddington-Cruz M, Botteman MF, et al.: Estimating the global prevalence of transthyretin familial amyloid polyneuropathy. Muscle Nerve 2018; 57: 829–37 CrossRef MEDLINE PubMed Central
6.Gonzalez-Lopez E, Gallego-Delgado M, Guzzo-Merello G, et al.: Wild-type transthyretin amyloidosis as a cause of heart failure with preserved ejection fraction. Eur Heart J 2015; 36: 2585–94 CrossRef MEDLINE
7.Tanskanen M, Peuralinna T, Polvikoski T, et al.: Senile systemic amyloidosis affects 25% of the very aged and associates with genetic variation in alpha2-macroglobulin and tau: a population-based autopsy study. Ann Med 2008; 40: 232–9 CrossRef MEDLINE
8.Benson MD, Buxbaum JN, Eisenberg DS, et al.: Amyloid nomenclature 2018: recommendations by the International Society of Amyloidosis (ISA) nomenclature committee. Amyloid 2018; 25: 215–9 CrossRef MEDLINE
9.Sekijima Y: Transthyretin (ATTR) amyloidosis: clinical spectrum, molecular pathogenesis and disease-modifying treatments. J Neurol Neurosurg Psychiatry 2015; 86: 1036–43 CrossRef MEDLINE
10.Ihne S, Morbach C, Obici L, Palladini G, Stork S: Amyloidosis in heart failure. Curr Heart Fail Rep 2019; 16: 285–303 CrossRef MEDLINE
11.Sekijima Y, Wiseman RL, Matteson J, et al.: The biological and chemical basis for tissue-selective amyloid disease. Cell 2005; 121: 73–85 CrossRef MEDLINE
12.Liepnieks JJ, Zhang LQ, Benson MD: Progression of transthyretin amyloid neuropathy after liver transplantation. Neurology 2010; 75: 324–7 CrossRef MEDLINE PubMed Central
13.Lousada I, Comenzo RL, Landau H, Guthrie S, Merlini G: Light chain amyloidosis: Patient experience survey from the amyloidosis research consortium. Adv Ther 2015; 32: 920–8 CrossRef MEDLINE PubMed Central
14.Lane T, Fontana M, Martinez-Naharro A, et al.: Natural history, quality of life, and outcome in cardiac transthyretin amyloidosis. Circulation 2019; 140: 16–26 CrossRef MEDLINE
15.Grogan M, Scott CG, Kyle RA, et al.: Natural history of wild-type transthyretin cardiac amyloidosis and risk stratification using a novel staging system. J Am Coll Cardiol 2016; 68: 1014–20 CrossRef MEDLINE
16.Coelho T, Maurer MS, Suhr OB: THAOS – The Transthyretin Amyloidosis Outcomes Survey: initial report on clinical manifestations in patients with hereditary and wild-type transthyretin amyloidosis. Curr Med Res Opin 2013; 29: 63–76 CrossRef MEDLINE
17.Quarta CC, Gonzalez-Lopez E, Gilbertson JA, et al.: Diagnostic sensitivity of abdominal fat aspiration in cardiac amyloidosis. Eur Heart J 2017; 38: 1905–8 CrossRef MEDLINE PubMed Central
18.Foli A, Palladini G, Caporali R, et al.: The role of minor salivary gland biopsy in the diagnosis of systemic amyloidosis: results of a prospective study in 62 patients. Amyloid 2011; 18 (Suppl 1): 80–2 CrossRef MEDLINE
19.Gillmore JD, Maurer MS, Falk RH, et al.: Nonbiopsy diagnosis of cardiac transthyretin amyloidosis. Circulation 2016; 133: 2404–12 CrossRef MEDLINE
20.Bochtler T, Hegenbart U, Kunz C, et al.: Translocation t(11;14) is associated with adverse outcome in patients with newly diagnosed AL amyloidosis when treated with bortezomib-based regimens. J Clin Oncol 2015; 33: 1371–8 CrossRef MEDLINE
21.Bochtler T, Hegenbart U, Kunz C, et al.: Prognostic impact of cytogenetic aberrations in AL amyloidosis patients after high-dose melphalan: a long-term follow-up study. Blood 2016; 128: 594–602 CrossRef MEDLINE
22.Bochtler T, Hegenbart U, Kunz C, et al.: Gain of chromosome 1q21 is an independent adverse prognostic factor in light chain amyloidosis patients treated with melphalan/dexamethasone. Amyloid 2014; 21: 9–17 CrossRef MEDLINE
23.Sanchorawala V, Palladini G, Kukreti V, et al.: A phase 1/2 study of the oral proteasome inhibitor ixazomib in relapsed or refractory AL amyloidosis. Blood 2017; 130: 597–605 CrossRef MEDLINE PubMed Central
24.Muchtar E, Dispenzieri A, Leung N, et al.: Depth of organ response in AL amyloidosis is associated with improved survival: grading the organ response criteria. Leukemia 2018; 32: 2240–9 CrossRef MEDLINE
25.Ericzon BG, Wilczek HE, Larsson M, et al.: Liver transplantation for hereditary transthyretin amyloidosis: after 20 years still the best therapeutic alternative? Transplantation 2015; 99: 1847–54 CrossRef MEDLINE
26.Muchtar E, Grogan M, Dasari S, Kurtin PJ, Gertz MA: Acquired transthyretin amyloidosis after domino liver transplant: phenotypic correlation, implication of liver retransplantation. J Neurol Sci 2017; 379: 192–7 CrossRef MEDLINE
27.Adams D, Gonzalez-Duarte A, O‘Riordan WD, et al.: Patisiran, an RNAi therapeutic, for hereditary transthyretin amyloidosis. N Engl J Med 2018; 379: 11–21 CrossRef MEDLINE
28.Solomon SD, Adams D, Kristen A, et al.: Effects of patisiran, an RNA interference therapeutic, on cardiac parameters in patients with hereditary transthyretin-mediated amyloidosis. Circulation 2019; 139: 431–43 CrossRef MEDLINE
29.Benson MD, Waddington-Cruz M, Berk JL, et al.: Inotersen treatment for patients with hereditary transthyretin amyloidosis. N Engl J Med 2018; 379: 22–31 CrossRef MEDLINE
30.Bulawa CE, Connelly S, Devit M, et al.: Tafamidis, a potent and selective transthyretin kinetic stabilizer that inhibits the amyloid cascade. Proc Natl Acad Sci USA 2012; 109: 9629–34 CrossRef MEDLINE PubMed Central
31.Sekijima Y, Dendle MA, Kelly JW: Orally administered diflunisal stabilizes transthyretin against dissociation required for amyloidogenesis. Amyloid 2006; 13: 236–49 CrossRef MEDLINE
32.Penchala SC, Connelly S, Wang Y, et al.: AG10 inhibits amyloidogenesis and cellular toxicity of the familial amyloid cardiomyopathy-associated V122I transthyretin. Proc Natl Acad Sci USA 2013; 110: 9992–7 CrossRef MEDLINE PubMed Central
33.Sant‘Anna R, Gallego P, Robinson LZ, et al.: Repositioning tolcapone as a potent inhibitor of transthyretin amyloidogenesis and associated cellular toxicity. Nat Commun 2016; 7: 10787 CrossRef MEDLINE PubMed Central
34.Coelho T, Maia LF, da Silva AM, et al.: Long-term effects of tafamidis for the treatment of transthyretin familial amyloid polyneuropathy. J Neurol 2013; 260: 2802–14 CrossRef MEDLINE PubMed Central
35.Coelho T, Maia LF, Martins da Silva A, et al.: Tafamidis for transthyretin familial amyloid polyneuropathy: a randomized, controlled trial. Neurology 2012; 79: 785–92 CrossRef MEDLINE PubMed Central
36.Maurer MS, Schwartz JH, Gundapaneni B, et al.: Tafamidis treatment for patients with transthyretin amyloid cardiomyopathy. N Engl J Med 2018; 379: 1007–16 CrossRef MEDLINE
37.Cardoso I, Martins D, Ribeiro T, Merlini G, Saraiva MJ: Synergy of combined doxycycline/TUDCA treatment in lowering transthyretin deposition and associated biomarkers: studies in FAP mouse models. J Transl Med 2010; 8: 74 CrossRef MEDLINE PubMed Central
38.Higaki JN, Chakrabartty A, Galant NJ, et al.: Novel conformation-specific monoclonal antibodies against amyloidogenic forms of transthyretin. Amyloid 2016; 23: 86–97 CrossRef MEDLINE PubMed Central
39.Comenzo RL, Reece D, Palladini G, et al.: Consensus guidelines for the conduct and reporting of clinical trials in systemic light-chain amyloidosis. Leukemia 2012; 26: 2317–25 CrossRef MEDLINE
40.Milani P, Basset M, Russo F, Foli A, Merlini G, Palladini G: Patients with light-chain amyloidosis and low free light-chain burden have distinct clinical features and outcome. Blood 2017; 130: 625–31 CrossRef MEDLINE
e1.Conceicao I, Coelho T, Rapezzi C, et al.: Assessment of patients with hereditary transthyretin amyloidosis – understanding the impact of management and disease progression. Amyloid 2019; 26: 103–11 CrossRef MEDLINE
e2.Conceicao I, Damy T, Romero M, et al.: Early diagnosis of ATTR amyloidosis through targeted follow-up of identified carriers of TTR gene mutations. Amyloid 2019; 26: 3–9 CrossRef CrossRef
e3.Gertz MA, Skinner M, Connors LH, Falk RH, Cohen AS, Kyle RA: Selective binding of nifedipine to amyloid fibrils. Am J Cardiol 1985; 55: 1646 CrossRef
e4.Pollak A, Falk RH: Left ventricular systolic dysfunction precipitated by verapamil in cardiac amyloidosis. Chest 1993; 104: 618–20 CrossRef MEDLINE
e5.Kristen AV, Dengler TJ, Hegenbart U, et al.: Prophylactic implantation of cardioverter-defibrillator in patients with severe cardiac amyloidosis and high risk for sudden cardiac death. Heart Rhythm 2008; 5: 235–40 CrossRef MEDLINE
e6.Gupta V, Lipsitz LA: Orthostatic hypotension in the elderly: diagnosis and treatment. Am J Med 2007; 120: 841–7 CrossRef MEDLINE
e7.Berk JL, Suhr OB, Obici L, et al.: Repurposing diflunisal for familial amyloid polyneuropathy: a randomized clinical trial. JAMA 2013; 310: 2658–67 CrossRef MEDLINE PubMed Central
e8.Kristen AV, Lehrke S, Buss S, et al.: Green tea halts progression of cardiac transthyretin amyloidosis: an observational report. Clin Res Cardiol 2012; 101: 805–13 CrossRef MEDLINE PubMed Central
e9.aus dem Siepen F, Bauer R, Aurich M, et al.: Green tea extract as a treatment for patients with wild-type transthyretin amyloidosis: an observational study. Drug Des Devel Ther 2015; 9: 6319–25 CrossRef MEDLINE PubMed Central
e10.Cappelli F, Martone R, Taborchi G, et al.: Epigallocatechin-3-gallate tolerability and impact on survival in a cohort of patients with transthyretin-related cardiac amyloidosis. A single-center retrospective study. Intern Emerg Med 2018; 13: 873–80 CrossRef MEDLINE
e11.Obici L, Cortese A, Lozza A, et al.: Doxycycline plus tauroursodeoxycholic acid for transthyretin amyloidosis: a phase II study. Amyloid 2012; 19 (Suppl 1): 34–6 CrossRef MEDLINE
e12.Gamez J, Salvadó M, Reig N: Transthyretin stabilization activity of the catechol-O-methyltransferase inhibitor tolcapone (SOM0226) in hereditary ATTR amyloidosis patients and asymptomatic carriers: proof-of-concept study. Amyloid 2019; 26: 74–84 CrossRef MEDLINE
e13.Judge DP, Heitner SB, Falk RH: Transthyretin stabilization by AG10 in symptomatic transthyretin amyloid cardiomyopathy. J Am Coll Cardiol 2019; 74: 285–95 CrossRef MEDLINE